Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

Oncology (Williston Park). 2021 Sep 14;35(9):528-535. doi: 10.46883/ONC.2021.3509.0528.

Authors

Bethany Smith¹, Sungjin Kim², Mourad Tighiouart², Edwin Posadas¹, Leland Chung¹, Robert Figlin¹, Neil Bhowmick¹, Jun Gong¹

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Biostatistics and Bioinformatics Research Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PMID: 34524771
DOI: 10.46883/ONC.2021.3509.0528

No abstract available

Publication types

Comparative Study
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Aged
Biomarkers, Tumor / blood*
Glutamine / blood*
Humans
Luminescent Measurements
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Prostatic Neoplasms / blood
Prostatic Neoplasms / mortality*
Prostatic Neoplasms / pathology
Retrospective Studies

Substances

Biomarkers, Tumor
Glutamine